Frequent relapse activity appears to be a key driver of disability accrual in patients with relapse-onset multiple sclerosis, indicates a study of patients receiving first-line injectable disease-modifying treatment.
Rebound syndrome following cessation of fingolimod for multiple sclerosis occurs at a clinically relevant rate, shows research, prompting the need for further study on how best to sequence and discontinue such drugs.
Oral antidiabetic medications have beneficial anti-inflammatory effects in patients with multiple sclerosis and metabolic syndrome, providing support for a link between metabolism and autoimmunity, researchers report.
The selective sphingosine 1-phosphate receptor inhibitor ozanimod significantly reduces lesion activity in patients with relapsing–remitting multiple sclerosis, shows a phase II study published in The Lancet Neurology.
Findings from the GATE study have shown equivalent efficacy and tolerability for a generic version of glatiramer acetate to that of the original brand version in the treatment of relapsing–remitting multiple sclerosis.
The DECIDE study shows that 4-weekly daclizumab high-yield process reduces disease activity in patients with relapsing–remitting multiple sclerosis more effectively than weekly interferon beta-1a, albeit at the cost of more adverse effects.
Researchers recommend extending the minimum timeframe for confirming disability progression in multiple sclerosis from 3–6 months to 12 or 24 months to better distinguish true irreversible disability from relapse-associated transient disability.